CNTA Stock Predictions
| Recent CNTA Stock Price | CNTA Stock Predictions | |
| $8.93 |  +17.58% |
$10.50 |
| Recent CNTA Analyst Ratings Breakdown, Making CNTA Stock Predictions | ||||
|---|---|---|---|---|
| Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
| Strong buy ratings: | 5 | 5 | 5 | 5 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 2 | 2 | 2 | 2 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.57 | 1.57 | 1.57 | 1.57 |
For the CNTA stock predictions from the analysts covering Centessa Pharmaceuticals PLC, we have collected all of the individual CNTA stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 6 different analysts covering CNTA (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since CNTA stock predictions may vary widely, another useful metric to consider is the median CNTA stock prediction, which represents the price at which half of the analysts
made CNTA stock predictions that were higher and half made CNTA stock predictions that were lower. This makes for a different take on the CNTA stock predictions out there, as compared to average or mean.
And that median across all the individual CNTA stock predictions was: $10.5 as of 2024-04-26.
The very highest of the CNTA stock predictions for one year price target was $15.0, while the very lowest of the CNTA stock predictions in the analyst group was
$5.0 (with a standard deviation of $3.728). Get the latest Zacks research report on CNTA — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
• DIN Stock Predictions
• NXST Stock Predictions
• TCFC Stock Predictions
• OEC Stock Predictions
• LNTH Stock Predictions
• TRNO Stock Predictions
• ADS Stock Predictions
• DKS Stock Predictions
• AJG Stock Predictions
|
|||||||||
|
|
|
|
|
|
Free Email Alerts:
Avg. Broker Rec.
 
|
Buy (3.43 out of 4) 57th percentile
(ranked higher than approx. 57% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|
|
